Journal
NEURO-ONCOLOGY
Volume 18, Issue 1, Pages 27-36Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/nov164
Keywords
blood-brain barrier; drug delivery; efflux transporters; glioma
Categories
Funding
- Merck
- Sanofi-Aventis
- Basilea
- Lilly
- Genentech
- Jazz Pharmaceuticals
- Medtronic Inc.
- Abbvie
- Novartis
- Pfizer
- Teva
- NATIONAL CANCER INSTITUTE [P30CA077598] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Glioblastoma (GBM) is a lethal and aggressive brain tumor that is resistant to conventional radiation and cytotoxic chemotherapies. Molecularly targeted agents hold great promise in treating these genetically heterogeneous tumors, yet have produced disappointing results. One reason for the clinical failure of these novel therapies can be the inability of the drugs to achieve effective concentrations in the invasive regions beyond the bulk tumor. In this review, we describe the influence of the blood-brain barrier on the distribution of anticancer drugs to both the tumor core and infiltrative regions of GBM. We further describe potential strategies to overcome these drug delivery limitations. Understanding the key factors that limit drug delivery into brain tumors will guide future development of approaches for enhanced delivery of effective drugs to GBM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available